Dr. P.Naina Mohamed
Pharmacologist
New Drug to Lower ‘LDL'
Cholesterol - Evolocumab
Introduction
 According to the results of a global trial, a new
injectable drug (Evolocumab) can further knock
down chole...
Possible Mechanism of
Action
Evolocumab (Human monoclonal antibody)
Monoclonal antibodies bind to PCSK9
Inhibition of bind...
Conclusion
 Evolocumab will be mostly helpful in treating people
with a genetic disorder that causes them to have high
ch...
References
 http://jama.jamanetwork.com/article.aspx?articleid
=1869210
 http://www.nlm.nih.gov/medlineplus/news/fullsto...
Upcoming SlideShare
Loading in …5
×

Evolocumab - New drug to lower ‘LDL' cholesterol

787
-1

Published on

Evolocumab is a monoclonal antibody and it inhibits Proprotein Convertase Subtilisin/kexin type 9 (PCSK9) to reduce LDL cholesterol in the bloodstream.

Published in: Education, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
787
On Slideshare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
25
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Evolocumab - New drug to lower ‘LDL' cholesterol

  1. 1. Dr. P.Naina Mohamed Pharmacologist New Drug to Lower ‘LDL' Cholesterol - Evolocumab
  2. 2. Introduction  According to the results of a global trial, a new injectable drug (Evolocumab) can further knock down cholesterol levels in people who take cholesterol-busting statin medications.  The lead author of the trial said that this drug enhances the body's natural way of reducing LDL levels in the bloodstream.  Evolocumab is a "human monoclonal antibody" which inhibits Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9).  PCSK9 is produced by liver and is a regulatory protein which targets LDL receptors for degradation and thereby reduces the liver's ability to remove LDL-
  3. 3. Possible Mechanism of Action Evolocumab (Human monoclonal antibody) Monoclonal antibodies bind to PCSK9 Inhibition of binding of PCSK9 with LDL receptors on the liver surface Increased number of LDL receptors Removal of LDL-C from the blood
  4. 4. Conclusion  Evolocumab will be mostly helpful in treating people with a genetic disorder that causes them to have high cholesterol.  It also could help people with high cholesterol who can't take large doses of statins.  An expert said a follow-up study is underway to evaluate Evolocumab's longer-term outcomes and safety. But if it does gain U.S. Food and Drug Administration approval, the drug will be expensive.  Evolocumab is a very specific antibody, it seems to be very well-tolerated without any drug interactions or any side effects.
  5. 5. References  http://jama.jamanetwork.com/article.aspx?articleid =1869210  http://www.nlm.nih.gov/medlineplus/news/fullstory _146222.html  http://www.nejm.org/doi/full/10.1056/NEJMoa131 6222  http://www.cardiosource.org/News- Media/Publications/Cardiology- Magazine/2014/03/Evolocumab.aspx
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×